Capecitabine plus gemcitabine in heavily pre-treated colorectal cancer. Results of an exploratory study.

3679 Background: Because daily oral capecitabine can mimic continuous infusion of 5-Fu and because gemcitabine can inhibit ribonucleotide reductase (Clin Cancer Res 1998; 4: 2811) resulting in enhanced binding of 5-Fu derivates to timidylate synthase and higher incorporation into DNA, a exoloratory study was initiated in September 2001. METHODS… CONTINUE READING